Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (171-180 of 212) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Future Oncology (London, England)|March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Pigment Cell & Melanoma Research|September 13, 2016
Melanoma central nervous system metastases: current approaches, challenges, and opportunitiesJustine V Cohen, Hussain Tawbi, Kim A Margolin, et al.
Cell|January 17, 2018
LXR/ApoE Activation Restricts Innate Immune Suppression in CancerMasoud F Tavazoie, Ilana Pollack, Raissa Tanqueco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Pageof 22

Showing results (171-180 of 212) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Future Oncology (London, England)|March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Pigment Cell & Melanoma Research|September 13, 2016
Melanoma central nervous system metastases: current approaches, challenges, and opportunitiesJustine V Cohen, Hussain Tawbi, Kim A Margolin, et al.
Cell|January 17, 2018
LXR/ApoE Activation Restricts Innate Immune Suppression in CancerMasoud F Tavazoie, Ilana Pollack, Raissa Tanqueco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Pageof 22